Area of research
Oncology · Pathology and Forensic Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, and RNA modifications and cancer.
Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer
Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study
Tissue factor expression in colorectal cancer.
Abstract P4-08-06: Clock Genes in Breast Cancer
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer
The impact of ARID1A mutation on molecular characteristics in colorectal cancer
B cell and B cell-related pathways for novel cancer treatments
The role of tumor angiogenesis as a therapeutic target in colorectal cancer
Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONO.
Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study
Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world
O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO
Locoregional treatment for advanced biliary tract cancer (aBTC): evaluation of efficacy and safety
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.